After weight loss, your body pushes back for years, so plan for that

Key takeaways

• Six years after “The Biggest Loser,” 14 contestants had regained about 90 of the 128 pounds they lost on average, and their bodies burned about 500 fewer calories a day at rest than their size would predict.
• In a 2001 analysis of 29 U.S. weight programs, people still had about two-thirds of their lost weight off after one year but only about a fifth after five years.
• In drugmaker-funded trials, people who stopped semaglutide regained about two-thirds of their loss within a year, and people switched from tirzepatide to a placebo regained about half.
• Medicare covers up to a year of intensive weight counseling in primary care with no coinsurance or deductible, and since July 1, 2026, a temporary program has offered certain GLP-1 drugs to eligible people for a $50 copay.
• By May 2026, the FDA had logged 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and it warns of counterfeit Ozempic sold in the U.S.

Researchers followed 14 contestants from the TV show “The Biggest Loser.” By the end of the 30-week contest, they had lost an average of 58 kilograms, about 128 pounds¹.

The researchers measured them again six years later. On average, they had regained about 41 kilograms, roughly 90 pounds by our conversion¹.

The bigger surprise was their metabolism. By the end of the show, their resting metabolic rate, the energy the body burns at rest, had dropped by about 600 calories a day¹. Six years later, it was still about 700 calories below where it started, and about 500 below what their body size would predict¹.

There was a twist. The contestants who had kept off the most weight showed the biggest slowdown at six years, and the slowdown at the show’s end didn’t predict who regained¹. The authors concluded that the slowdown lasts, and that it grows with weight loss without fully canceling it out¹.

Their bodies, in other words, were still pushing back. That’s biology, not a character flaw. It helps explain why regain is the usual pattern after almost any weight-loss treatment ends, including the new GLP-1 drugs.

Your body pushes back, so regain is the rule

Ordinary dieters show the same pattern.

In a 2011 Australian study in the New England Journal of Medicine, 50 adults with overweight or obesity lost an average of 13.5 kilograms, about 30 pounds, on a 10-week very-low-calorie diet². A year later, hormones that govern hunger and fullness, including ghrelin and leptin, still hadn’t returned to their earlier levels, and neither had people’s hunger ratings².

A 2020 international consensus statement on obesity summed it up. Losing weight on purpose sets off changes in appetite and metabolism that tend to drive weight back up, and those changes can last³. The panel added that expecting lifestyle change alone to fully reverse obesity over the long run, even when it is severe, goes against the evidence³.

In 2001, researchers pooled 29 U.S. weight-loss programs that followed people for at least two years⁴.

People lost an average of 14 kilograms, about 31 pounds, at first. How much of that loss they still had off⁴:

• After 1 year: 67%
• After 2 years: 44%
• After 3 years: 32%
• After 5 years: about 21%, based on only eight studies

At an average of four and a half years, people were about 3 kilograms, or 6.6 pounds, below their starting weight⁴. That’s modest, but it isn’t zero. The analysis was partly funded by Health Management Resources, a commercial weight-loss program⁴. Our article on setbacks covers longer results from the Look AHEAD trial and the National Weight Control Registry.

Behavior programs: modest loss, few harms, and Medicare pays

In 2018 the U.S. Preventive Services Task Force, a national expert panel on prevention, gave a “B” grade to intensive behavioral programs for adults with a BMI of 30 or higher⁵. BMI, or body mass index, is weight scaled to height.

“Intensive” means many sessions. Most programs in the Task Force’s review ran one to two years and held at least 12 sessions in the first year; group programs had a median of 23⁵. They taught self-monitoring of weight, problem solving, peer support and planning for slips⁵.

The results were real but modest⁵:

• Weight: about 2.4 kilograms (5 pounds) more loss than comparison groups at 12 to 18 months, across 67 trials and more than 22,000 people.
• Reaching a 5% loss: about twice as likely. For every 8 people in a program, 1 more reached that mark than would have without it.
• Diabetes: about a third fewer new cases across nine studies. In Finland’s long-running prevention study, 40% of the lifestyle group had diabetes after nine years, compared with 54.5% of the comparison group.
• Staying there: programs built for maintenance cut regain by about 1.6 kilograms (3.5 pounds) in eight studies.
• Harms: small to none.

The Task Force reviewed older weight-loss drugs, not semaglutide or tirzepatide⁵.

Medicare pays for this kind of counseling under a coverage rule known as NCD 210.12⁶. If your BMI is 30 or more, a primary care clinician can see you weekly in month one and every other week through month six⁶. If you’ve lost at least 3 kilograms (6.6 pounds) by then, monthly visits continue through month 12⁶. That’s up to about 22 visits in a year, by our math, with no coinsurance or Part B deductible⁶.

GLP-1 drugs keep working only while you take them

GLP-1 drugs copy a hormone the gut releases after eating, which tells the brain to turn hunger down⁹. The best known are semaglutide, sold as Ozempic, Wegovy and Rybelsus, and tirzepatide, sold as Mounjaro and Zepbound⁹.

The STEP 1 trial gave adults weekly semaglutide or a placebo, plus the same lifestyle counseling, for 68 weeks⁷. Among the 327 people followed afterward, the semaglutide group had lost 17.3% of their weight, compared with 2.0% on placebo⁷.

Then all treatment stopped, counseling included. Within a year, the semaglutide group regained 11.6 percentage points, about two-thirds of what they had lost. They ended 5.6% below their starting weight, compared with 0.1% for placebo⁷. Blood pressure returned to where it began, and blood sugar and cholesterol gave back part of their gains⁷.

The drugmaker Novo Nordisk funded the trial, and three authors worked for the company⁷. The authors concluded that ongoing treatment is needed to keep the benefits⁷.

Tirzepatide, made by Eli Lilly⁹, shows a similar pattern. In the SURMOUNT-4 trial, published in JAMA, 670 people who had taken tirzepatide for 36 weeks were randomly assigned to keep taking it or switch to a placebo⁸. Over the next year, the placebo group regained 14% of their body weight, about half of what they had lost, though they stayed almost 10% below where they started⁸. Lilly sponsored the trial, and lead researcher Louis Aronne of Weill Cornell Medicine is a paid Lilly adviser⁸.

Side effects are common. Nausea, vomiting, constipation, diarrhea and headaches top the list, according to a 2026 Stanford Medicine article⁹. Our article on preserving muscle covers how much lean tissue people lose on these drugs and how strength training helps.

If you take one of these drugs, plan any change in dose or any decision to stop with your prescriber.

What GLP-1 drugs cost, and what Medicare and Medicaid cover in 2026

Brand-name GLP-1 drugs list for more than $1,000 a month⁹. And ever since Medicare’s drug benefit, Part D, was created, Medicare has been barred from paying for weight-loss drugs¹⁰. That began to change after November 2025 agreements between the Trump administration and the two makers, Novo Nordisk and Eli Lilly, which led to two new federal programs. Under them, the makers supply the drugs at a net price of $245 a month¹⁰.

Where things stood in October 2026, based on analyses by George Washington University’s STOP Obesity Alliance and the Obesity Medicine Association¹⁰¹¹:

• Medicare GLP-1 bridge. This stopgap opened July 1, 2026, and runs through December 31, 2027, a year longer than first planned¹⁰¹¹. It works outside regular Part D plans. If you have Medicare drug coverage and meet clinical criteria, it can cover Wegovy, Zepbound or Foundayo for $50 per fill¹⁰¹¹. Your prescriber seeks prior approval from a central processor, not your own plan¹⁰¹¹.
• BALANCE model, Medicare side. It won’t launch for Medicare in 2027, and CMS has said 2028 at the earliest¹⁰¹¹.
• BALANCE model, Medicaid side. Still going ahead. States could sign up through mid-2026 and start as late as January 1, 2027; in April, it wasn’t yet clear which states would take part¹⁰¹¹.
• Congress. Lawmakers have introduced the Treat and Reduce Obesity Act to let Part D cover obesity medicines. As of GWU’s April analysis, it was still only a proposal¹⁰.

Rules are changing fast, so confirm the details with your plan or state Medicaid office.

Surgery is the strongest tool, and the least used

Weight-loss surgery, also called metabolic or bariatric surgery, works partly through biology. The 2020 consensus panel noted that it tends to lower appetite and raise metabolic rate, the opposite of what dieting does, and that it produces major, long-term weight loss³.

Yet only 0.1% to 2% of people who qualify worldwide have it³. Many insurers limit coverage, and in one U.S. survey just 19.2% of respondents supported insurers paying for it³. The panel also rejected the stereotype that surgery is an “easy way out”³.

The UK’s national obesity guideline calls for referral to specialist services for adults with complex needs, including when surgery is being considered¹³. Ask any surgical program for its own long-term results and how it supports patients for years afterward.

Habits that go with keeping weight off

The evidence here comes mostly from small studies, but a few patterns stand out.

• Movement. In six studies in the 2001 analysis, groups that exercised more kept off about 15 kilograms, compared with about 7.5 kilograms in less active groups⁴. That shows a link, not proof that exercise caused the difference.
• Checking in on yourself. Self-monitoring of weight is a core piece of the programs the Task Force graded⁵. The UK guideline suggests weighing once a week, but warns of risks for people prone to disordered eating¹³.
• Protein. In the DIOGENES trial of 773 adults, a higher-protein diet with lower-glycemic carbohydrates helped people keep weight off; smaller trials are mixed¹⁴.
• Fiber. Fiber pills and added whole grains didn’t help maintenance in two small trials¹⁴. Our fiber article covers its other benefits.
• Steady, livable changes. The guideline advises against extreme diets or workouts that are hard to keep up, and suggests spotting the situations that tend to derail you¹³.

Our article on sleep and metabolism covers how sleep affects appetite.

If tracking food or weight starts to bring anxiety, restriction or bingeing, stop and get support. Eating disorders occur at any weight¹³. The National Alliance for Eating Disorders helpline, 1-866-662-1235, is free and staffed by licensed therapists on weekdays¹⁵.

The maintenance plan, phase by phase

Use this as a guide to discuss with your clinician; ratings use our four-level evidence scale.

Phase	What helps (evidence rating)	Recheck with a clinician if…
First 6 months	A structured program with frequent visits; Medicare covers one in primary care (Strong evidence)56. Movement you enjoy most days (Promising but early)4	On a GLP-1 drug, get care promptly for sharp pain in the upper belly and back, signs of severe dehydration such as fainting, confusion or no urine for eight hours, or stomach symptoms that worsen instead of easing9
Months 6 to 12	Keep regular check-ins; Medicare’s monthly visits continue after a 3-kilogram loss (Strong evidence)56. Protein-rich meals (Promising but early)14. Weekly weighing only if it helps you (Promising but early)513	Tracking brings anxiety, restriction or bingeing; call the eating-disorders helpline1315
Year 2 and beyond	A maintenance-focused program (Promising but early)5. If you take a GLP-1, expect regain if it stops and plan any change with your prescriber (Strong evidence)78	After stopping a drug or regaining weight, ask for blood pressure, blood sugar and cholesterol checks, since all three worsened after semaglutide stopped7
Any time	Buy drugs only by prescription from a state-licensed pharmacy (FDA safety advice)12	An injectable arrives warm, or a product is labeled “for research”; report problems to MedWatch12

How strong is the evidence?

Claim	Evidence level	What it rests on
The body defends lost weight through hunger hormones and slower metabolism	Strong evidence	Hormone and metabolism studies; expert consensus123
Most people regain much of their loss once a program ends	Strong evidence	29 U.S. programs followed two years or more4
Intensive behavioral programs bring modest loss with few harms	Strong evidence	67 trials reviewed by the Task Force5
Maintenance-focused programs reduce regain	Promising but early	Eight studies; small average effect5
GLP-1 drugs keep weight off only while taken	Strong evidence	Two drug-withdrawal trials, both company-funded78
Surgery produces major, lasting weight loss	Strong evidence	International expert consensus citing long-term studies3
More exercise goes with less regain	Promising but early	Comparisons within six studies; cause unproven4
Higher-protein eating helps maintenance	Promising but early	One large trial; smaller trials mixed14
Fiber supplements help maintenance	Not enough evidence	Two small trials found no effect14
Compounded or “research” GLP-1 products are a safe shortcut	Evidence says no, or unsafe	FDA adverse-event reports and warnings12

Judge success by health, not just the scale

The STEP 1 extension shows why health markers deserve a place on your scorecard. As weight came back, blood pressure, blood sugar and cholesterol moved with it⁷. The Task Force counted fewer cases of diabetes, not only pounds⁵.

So measure what matters to you: blood pressure, blood sugar, cholesterol, how far you can walk, how you sleep and how your joints feel. A smaller loss you keep may serve you better than a bigger one that comes back. The UK guideline makes a similar point: small, gradual changes are likely to help, and no single food or activity holds weight steady¹³.

Natural health has long taught respect for the body’s wisdom. Its fierce defense of its weight can be seen as a protective system, not an enemy. Working with it means patience, habits you can keep for years, and treatment chosen on evidence rather than shame. Our companion article on weight stigma covers why blame backfires and how to get respectful care.

Questions readers ask

The bottom line

Regain after weight loss is the body defending itself, not a personal failure. Hunger hormones and a slower metabolism can linger for years, and weight returns for most people when a program or a drug stops.

What helps is a long view: a program with regular contact, movement you enjoy, meals that keep you full, and a clear plan with your clinician for any medicine. Measure success by your blood pressure, blood sugar, strength and daily life, and get support if tracking turns into distress.

Related reading

• Doctors share the public’s weight bias, and you can protect your care from it
• A slip doesn’t erase your progress, but your reaction to it can
• Frail 90-year-olds nearly tripled their strength, proof that muscle responds at any age
• Eight eating patterns compared, and why the diet you stick with beats the one you pick
• Short sleep blunts insulin and stokes appetite, and adding sleep cut calories

Sources

1. Fothergill E, Guo J, Howard L, Kerns JC, Knuth ND, Brychta R, Chen KY, Skarulis MC, Walter M, Walter PJ, Hall KD. “Persistent metabolic adaptation 6 years after ‘The Biggest Loser’ competition.” Obesity, 2016;24(8):1612–1619 (abstract via CARTA bibliography record). carta.anthropogeny.org
2. Sumithran P, Prendergast LA, Delbridge E, et al. “Long-term persistence of hormonal adaptations to weight loss.” New England Journal of Medicine, 2011;365(17):1597–1604 (Austin Health repository record). ahro.austin.org.au
3. Rubino F, Puhl RM, Cummings DE, et al. “Joint international consensus statement for ending stigma of obesity.” Nature Medicine, 2020;26:485–497 (author manuscript, UCL Discovery). pubmed.ncbi.nlm.nih.gov
4. Anderson JW, Konz EC, Frederich RC, Wood CL. “Long-term weight-loss maintenance: a meta-analysis of US studies.” American Journal of Clinical Nutrition, 2001;74:579–584. gwern.net
5. US Preventive Services Task Force. “Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement.” JAMA, 2018;320(11):1163–1171 (eScholarship copy). escholarship.org
6. Centers for Medicare & Medicaid Services. “National Coverage Determination: Intensive Behavioral Therapy for Obesity (210.12).” CMS Medicare Coverage Database. cms.gov
7. Wilding JPH, Batterham RL, Davies M, et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension.” Diabetes, Obesity and Metabolism, 2022 (UCL Discovery). pubmed.ncbi.nlm.nih.gov Obesity Metabolism – 2022 – Wilding – Weight regain and cardiometabolic effects after withdrawal of semaglutide .pdf
8. Weill Cornell Medicine. “Tirzepatide Enhances Weight Loss with Sustained Treatment but Discontinuation Leads to Weight Regain.” News release, December 11, 2023 (on Aronne LJ, et al., SURMOUNT-4, JAMA, 2024;331:38–48; trial sponsored by Eli Lilly and Company). news.weill.cornell.edu
9. Williams S. “Compounded GLP-1s: Why doctors worry and the FDA is cracking down.” Stanford Medicine Insights, July 16, 2026. med.stanford.edu
10. Gallagher C. “A Pathway to Coverage of GLP-1s in Medicare and Medicaid.” STOP Obesity Alliance, George Washington University, April 30, 2026. stop.publichealth.gwu.edu
11. Obesity Medicine Association. “Updates to Medicare Coverage of GLP-1 Medications.” OMA blog, published May 17, 2026, updated July 14, 2026. obesitymedicine.org
12. U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” FDA, content current as of October 1, 2026. fda.gov
13. National Institute for Health and Care Excellence. “Overweight and obesity management” (NG246). NICE, published January 14, 2025, updated January 8, 2026. nice.org.uk
14. van Baak MA, Mariman ECM. “Dietary Strategies for Weight Loss Maintenance.” Nutrients, 2019;11(8):1916. pubmed.ncbi.nlm.nih.gov
15. National Alliance for Eating Disorders. Helpline information (homepage). Accessed October 2026. allianceforeatingdisorders.com